Recursion Pharmaceuticals is a strong candidate to become a next-generation trillion-dollar company, as a drug factory that designs itself. Tomorrow's trillion-dollar companies are learning to read and write biology. x.com 

Voyager Technologies is a space company in the right sector at the right time, with a growing, mostly government backlog of $275M. Revenue is very small against its $2B market cap and the company burns cash, but $429M of cash against a $67M quarterly burn implies 2-3 years of runway before it would urgently need to raise capital. It was not a favorite in earlier space research, but the stock is breaking out of a wedge that looks good to the mid-$40s as a swing trade. x.com 

Recursion Pharmaceuticals looks like a falling knife despite a compelling idea behind the company. @WessexCapital calls it a financial disaster that is perpetually raising money. A large capital raise and the resulting drop would be the signal to consider it, perhaps around $1, as a lottery-style venture bet. x.com 

AI-for-science stocks show a typical pump-and-dump setup driven by Chinese and Hong Kong hedge funds, and more pumps and dumps are likely. These funds trade narratives and price in an extremely bright future, so consensus forms fast and crowded positions reverse easily. When Chinese sell-side analysts or the Chinese community on X are loud about a thesis, it is a trade to avoid. Fundamentals still look exciting, and key moving averages are the signal to re-enter long. x.com  x.com